Ribociclib Succinate is the succinate salt form of ribociclib, an orally available inhibitor of the cyclin-dependent kinases (CDKs) 4 and 6, with antineoplastic activity. Upon oral administration, ribociclib specifically targets, binds to and inhibits CDK4 and CDK6. This inhibits the cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, which inhibits phosphorylation of the retinoblastoma (Rb) protein. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle dysregulation. It is grouped under the following drug class(es): Antineoplastic agents, CDK4/6 Inhibitors and Kinase inhibitors. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include LEE-011 succinate, LEE011-BBA, Birociclib and Kisqali. Its PubChem CID is 57334219.
Ribociclib succinate
| CAS No | 1374639-75-4 |
|---|---|
| Molecular Formula | C27H36N8O5 |
| Molecular Weight | 552.6 g/mol |
| Synonyms | butanedioic acid;7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Ribociclib Succinate is the succinate salt form of ribociclib, an orally available inhibitor of the cyclin-dependent kinases (CDKs) 4 and 6, with antineoplastic activity.
The listed CAS number is 1374639-75-4.
The listed molecular formula is C27H36N8O5.
The listed molecular weight is 552.6 g/mol.
butanedioic acid;7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide.
The source lists LEE-011 succinate, LEE011-BBA, Birociclib and Kisqali.